Cerus Co. (NASDAQ:CERS) – Equities researchers at Cantor Fitzgerald issued their FY2017 earnings per share (EPS) estimates for Cerus in a report issued on Sunday, according to Zacks Investment Research. Cantor Fitzgerald analyst C. Bijou forecasts that the biotechnology company will post earnings of ($0.59) per share for the year. Cantor Fitzgerald currently has a “Buy” rating and a $5.00 target price on the stock. Cantor Fitzgerald also issued estimates for Cerus’ FY2018 earnings at ($0.43) EPS and FY2019 earnings at ($0.27) EPS.
CERS has been the subject of several other reports. Robert W. Baird reaffirmed a “buy” rating and set a $5.00 price objective on shares of Cerus in a research report on Friday, December 1st. Zacks Investment Research cut Cerus from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. BidaskClub cut Cerus from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th. Cowen set a $6.00 price objective on Cerus and gave the stock a “buy” rating in a research report on Thursday, October 5th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Cerus in a research report on Friday, December 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Cerus currently has a consensus rating of “Hold” and an average target price of $5.83.
Cerus (NASDAQ:CERS) opened at $4.01 on Wednesday. The stock has a market capitalization of $499.20, a PE ratio of -6.80 and a beta of 1.93. Cerus has a 1 year low of $1.93 and a 1 year high of $4.70. The company has a current ratio of 3.71, a quick ratio of 3.11 and a debt-to-equity ratio of 0.80.
Cerus (NASDAQ:CERS) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. The firm had revenue of $10.80 million during the quarter, compared to analysts’ expectations of $11.95 million. During the same period in the previous year, the firm posted ($0.14) EPS. Cerus’s revenue for the quarter was up 5.9% on a year-over-year basis.
Several institutional investors have recently bought and sold shares of CERS. Marshall Wace North America L.P. purchased a new stake in shares of Cerus in the 2nd quarter valued at about $316,000. Stephens Inc. AR lifted its holdings in shares of Cerus by 1.4% in the 2nd quarter. Stephens Inc. AR now owns 963,702 shares of the biotechnology company’s stock valued at $2,419,000 after purchasing an additional 12,973 shares during the last quarter. Teachers Advisors LLC lifted its holdings in shares of Cerus by 9.7% in the 2nd quarter. Teachers Advisors LLC now owns 260,081 shares of the biotechnology company’s stock valued at $653,000 after purchasing an additional 22,896 shares during the last quarter. Elk Creek Partners LLC lifted its holdings in shares of Cerus by 32.3% in the 2nd quarter. Elk Creek Partners LLC now owns 5,739,285 shares of the biotechnology company’s stock valued at $14,406,000 after purchasing an additional 1,402,106 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its holdings in shares of Cerus by 59.3% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 48,377 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 18,000 shares during the last quarter. 55.72% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.truebluetribune.com/2018/01/17/cantor-fitzgerald-weighs-in-on-cerus-co-s-fy2017-earnings-cers.html.
Cerus Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.